Endothelial activation and subclinical microvascular occlusions are an ongoing process during steady-state sickle cell disease, leading to interleukin production and an acute-phase response. Alpha-2-macroglobulin (α2M) is an acute-phase protein mainly regulated by interleukin-6 (IL-6). On the other hand, α2M acts as a carrier protein for IL-6 during inflammatory stress. The purpose of this study is to further assess the interactions between IL-6 and α2M as potent modulators of inflammatory reactions during the steady state of sickle cell disease. We measured α2M and IL-6 levels in 21 patients (12 male, 9 female; age range 12–44 years) in the steady state of sickle cell disease. Four patients had homozygous sickle cell anaemia and 17 had double heterozygous sickle cell/β-thalassaemia. Diagnostic quantification of α2M was performed by rate nephelometry. Commercial enzyme immunoassay test kits were used for the quantitative measurement of IL-6. The α2M and IL-6 levels were compared to the values obtained from healthy volunteers. Mean values (± SD) of α2M and IL-6 were found to be significantly increased (p < 0.0005) in the patients (α2M: 337.2 ± 104 mg/dl; IL-6: 4 ± 2.1 pg/ml) compared to the healthy controls (α2M: 204.2 ± 45.8 mg/dl; IL-6: 1.15 ± 2.5 pg/ml). IL-6 values were positively correlated with α2M levels (r = 0.61, p < 0.01). We observed increased α2M and IL-6 levels in steady-state sickle cell disease and a positive correlation between these two inflammatory mediators. We suggest that α2M is a potent modulator of the inflammatory reaction and tissue repair mechanism during steady-state microvascular occlusions. Elucidating the role of α2M in sickle cell disease could lead to the development of novel strategies and therapies for preventing the harmful systemic or local effects of excess cytokine production.

1.
Francis RB, Johnson CS: Vascular occlusion in sickle cell disease: Current concepts and unanswered questions. Blood 1991;77:1405–1414.
2.
Platt OS, Thorington B, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR: Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11–16.
3.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–1644.
4.
Akinola NO, Stevens SM, Franklin IM, Nash GB, Stuart J: Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 1992;45:902–906.
5.
Hebbel RP: Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;99:2561–2564.
6.
Singhal A, Doherty JF, Raynes JG, McAdam KP, Thomas PW, Serjeant BE, Serjeant GR: Is there an acute-phase response in steady-state sickle cell disease? Lancet 1993;341:651–653.
7.
Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74–80.
8.
Sottrup-Jensen L: Alpha2-macroglobulin and related thiol ester plasma proteins; in Putnam FW (ed): The Plasma Proteins. Orlando, Academic Press, 1987, vol 5, pp 192–291.
9.
Borth W: Alpha 2-macroglobulin: A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. Ann NY Acad Sci 1994;737:267–272.
10.
Chu CT, Pizzo SV: α2-Macroglobulin, complement, and biologic defense: Antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest 1994;71:792–812.
11.
Matsuda T, Hirano T, Nagasawa SH, Kishimoto T: Identification of α2-macroglobulin as a carrier protein for IL-6. J Immunol 1989;142:148–152.
12.
Dacie JV, Lewis SM: Practical Haematology, ed 6. Edinburgh, Churchill Livingstone, 1984, pp 179–198.
13.
El-Hazmi MAF, Warsy AS, Al-Momen AK, Harakati M: Hydroxyurea for the treatment of sickle cell disease. Acta Haematol 1992;88:170–174.
14.
Hedo CC, Aken’ova YA, Okpala IE, Durojaiye AO, Salimonu LS: Acute phase reactants and severity of homozygous sickle cell disease. J Intern Med 1993;233:467–470.
15.
Monnet D, Diallo I, Sangare A, Yapo AE: Clinical value of C-reactive protein, alpha 1-glycoprotein acid and transferrin assay in homozygous sickle cell disease. Bull Soc Pathol Exot 1993;86:282–285.
16.
Moore C, Ehlayel M, Inostroza J, Leiva LE, Kuvibidila S, Yu L, Gardner R, Ode DL, Warrier R, Sorensen RU: Increased circulating levels of soluble HLA class I heterodimers in patients with sickle cell disease. J Natl Med Assoc 1998;90:157–163.
17.
Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A: Acute-phase proteins and interleukins during the steady state of sickle cell disease. Eur J Haematol 1998;61:49–54.
18.
Taylor SC, Shacks SJ, Mitchell RA, Banks A: Serum interleukin-6 levels in the steady state of sickle cell disease. J Interferon Cytokine Res 1995;15:1061–1064.
19.
Rautonen N, Martin NL, Rautonen J, Rooks Y, Mentzer WC, Wara D: Low number of antibody producing cells in patients with sickle cell anemia. Immunol Lett 1992;34:207–211.
20.
Kasschau MR, Barabino GA, Bridges KR, Golan DE: Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1993;87:771–780.
21.
James K: Interactions between cytokines and α2-macroglobulin. Immunol Today 1990;11:163–166.
22.
Crookston KP, Webb DJ, Wolf BB, Gonias SL: Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem 1994;269:1533–1540.
23.
LaMarre J, Wollenberg GK, Gonias SL, Hayes MA: Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest 1991;65:3–14.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.